Skip to content
Open access

A clinical pilot study for personalized risk-based breast cancer screening utilizing a polygenic risk score

Jul 2026 · PLoS ONE · Vol 21, pp. e0345431 · 0 citations · 30 references
Medicine

TL;DR

In this pilot cohort, PRS-based risk stratification led to earlier or more intensive screening recommendations in half of the participants, while family history also influenced management.

Abstract

Background Population-based mammographic screening is primarily age-based. However, breast cancer risk is multifactorial, and women may benefit from personalized risk-based screening. This pilot study aimed to explore the use of polygenic risk score (PRS) as a tool for risk stratification in personalized screening. Methods We included 80 women aged 40–49 years referred for clinical mammography. Exclusion criteria were prior breast cancer or premalignant breast disease, and previous genetic testing. After DNA collection, PRS was calculated from 2805 Single Nucleotide Polymorphisms (SNPs). Screening recommendations were based on each participant’s relative 10-year breast cancer risk estimated from PRS and compared with the 10-year risk of an average woman of the same age. Women with a self-reported family history of cancer meeting standard criteria were referred for gene panel testing for pathogenic variants in high-risk genes. A follow up questionnaire regarding participants’ experiences was distributed 6–9 months after PRS testing. Results Mean age was 45.2 years (SD 2.8). Mean relative 10-year breast cancer risk was 1.18 (SD 0.57). Based on PRS, 40 participants were recommended standard biennial screening 50–69 years, while 40 were advised to begin biennial screening before age 50. Among these, 7 were recommended annual mammography from when their 10-year risk reached twice that of an average 50-year-old. Twenty-one women underwent gene panel testing; no pathogenic variants in breast cancer genes were identified. Five women were advised annual mammography from 40–60 years due to family history of breast cancer, regardless of PRS. Most respondents viewed breast cancer risk assessment positively and did not report increased anxiety after testing. Conclusions In this pilot cohort, PRS-based risk stratification led to earlier or more intensive screening recommendations in half of the participants, while family history also influenced management.

Read PDF

Similar papers

Open access Jul 2026

Real-World Evidence for Breast Cancer Risk Stratification: Insights from the P.I.N.K. Study

This study identified several personal characteristics that were more strongly linked to breast cancer occurrence, highlighting the value of integrating clinical and self-reported information to better understand individual risk and support more targeted prevention and screening efforts.

M. Franchini, F. Denoth, Stefania Pieroni et al. · 0 citations
Review Open access Aug 2026

Genetic testing for breast cancer—adherence, outcomes and impact on surgical management: a quality review

Hereditary breast cancer accounts for approximately 10% of all breast cancer cases. Swedish national breast cancer guidelines specify criteria for germline genetic testing. This quality review aimed to investigate the adherence to these criteria at diagnosis of breast cancer, the prevalence of pathogenic variants...

Bi-Ying Huang, Anne Kinhult Stålbom, Svetlana Bajalica Lagercrantz et al. · 0 citations
Open access Sep 2026

Genetic risk stratification of common diseases in breast cancer survivors: a population-based cohort study.

IMPORTANCE Patients diagnosed with breast cancer (BCa) are at increased risk of multiple common diseases; however, the spectrum of these diseases and the contribution of inherited genetic susceptibility remain incompletely characterized. METHODS We evaluated 15 common diseases and tested their associations with BCa e...

Annabelle Ashworth, Zhu-Qing Shi, Huy Tran et al. · 0 citations
Open access Jul 2026

Temporal changes in breast cancer lifetime risk and implications for personalised surveillance in high-risk women

To evaluate temporal changes in breast cancer lifetime risk (BC-LTR) over a 10-year period among women with clinically elevated risk but without known pathogenic genetic mutations, using the International Breast Cancer Intervention Study (IBIS) breast cancer risk evaluation tool, and to assess implications for personal...

M. Keupers, Sam Nijssen, Willem Sarkol et al. · 0 citations
Review Open access Aug 2026

Priorities for breast cancer risk assessment in UK women under age 50: a survey and discrete choice experiment.

BACKGROUND National guidelines recommend English women between 30 and 49 years with moderate/high risk of breast cancer (BC) be offered screening and prevention interventions. Identification  largely relies on family history-based criteria amongst women self-presenting in primary care. We aimed to understand the prefer...

Rebecca A. Dennison, Maria Valasaki, S. Wright et al. · 0 citations
Open access Aug 2026

Risk-Reducing Interventions in Women With Pathogenic Variants in Breast Cancer Susceptibility Genes

PURPOSE Recommendations for clinical management of women with germline pathogenic variants (PVs) in breast cancer susceptibility genes vary by gene. The goal of this study was to examine the utilization of risk-reducing strategies and treatments in women with germline PVs in breast cancer susceptibility genes. METHODS...

Emily M. Russell, S. Nielsen, R. Ellsworth et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.